Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Sangamo Therapeutics Inc    SGMO

Delayed Quote. Delayed  - 11/22 10:00:00 pm
15 USD   -0.66%
11/15 SANGAMO THERAPE : Hikes on Genome Editing
11/15 SANGAMO THERAPE : Announces Treatment of First Patient in Landmark P..
11/09 SANGAMO THERAPE : reports 3Q loss
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Sangamo Biosciences : Technical Briefing on Biotechnology Equities -- MannKind, Novavax, Incyte, BioMarin Pharma, and Sangamo Biosciences

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/23/2015 | 02:07pm CET

NEW YORK, September 23, 2015 /PRNewswire/ --

Equity Research Institute has initiated coverage on the following equities: MannKind Corporation (NASDAQ: MNKD), Novavax Inc. (NASDAQ: NVAX), Incyte Corporation (NASDAQ: INCY), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and Sangamo Biosciences Inc. (NASDAQ: SGMO). Free research report on MannKind can be accessed at https://www.erionline.net/MNKD.pdf On Tuesday, September 22, 2015, the NASDAQ Composite ended at 4,756.72, down 1.50%, the Dow Jones Industrial Average lost 1.09%, to finish the day at 16,330.47, and the S&P 500 closed at 1,942.74, down 1.23%. The losses were broad based as eight out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.  

MannKind Corp.'s stock lost 3.57%, to close the day at $3.24. The stock recorded a trading volume of 4.88 million shares, much below its three months average volume of 5.09 million shares. Over the last one month and over the past three months, MannKind Corp.'s shares have declined 14.51% and 45.45%, respectively. Furthermore, the stock has plummeted 37.87% since the start of this year. The company's shares are trading 23.62% below their 50-day moving average. Additionally, MannKind Corp. has a Relative Strength Index (RSI) of 32.18. Sign up and read the free notes on MNKD at:

https://www.erionline.net/MNKD.pdf

On Tuesday, shares in Novavax Inc. recorded a trading volume of 4.15 million shares, lower than their three months average volume of 5.12 million shares. The stock ended the day 1.41% lower at $9.77. Novavax Inc.'s stock has plummeted 19.59% in the last one month and 12.06% in the previous three months. However, the stock has surged 64.76% on YTD basis. The company is trading above its 200-day moving average by 7.53%. Furthermore, shares of Novavax Inc. have an RSI of 40.56. The complimentary notes on NVAX can be downloaded in PDF format at:

https://www.erionline.net/NVAX.pdf

Incyte Corp.'s stock edged 0.74% lower, to close Tuesday's session at $117.78. The stock recorded a trading volume of 1.64 million shares, above its three months average volume of 1.23 million shares. Over the last one month and the previous three months, Incyte Corp.'s shares have gained 12.91% and 7.75%, respectively. Additionally, the stock has surged 61.10% since the start of this year. The company is trading 3.91% and 21.43% above its 50-day and 200-day moving averages, respectively. Furthermore, Incyte Corp.'s stock traded at a PE ratio of 2944.50 and has an RSI of 48.64. Register for free on Equity Research Institute and access the latest research on INCY at:

https://www.erionline.net/INCY.pdf

BioMarin Pharmaceutical Inc.'s stock finished Tuesday's session 3.37% lower at $117.97. A total of 2.26 million shares were traded, which was above its three months average volume of 1.22 million shares. Over the last one month and the previous three months, BioMarin Pharmaceutical Inc.'s shares have fallen by 6.50% and 15.04%, respectively. However, the stock has surged 30.50% since the beginning of 2015. The company's shares are trading below their 50-day and 200-day moving averages by 13.47% and 0.79%, respectively. BioMarin Pharmaceutical Inc.'s stock has an RSI of 33.99. The complete research on BMRN is available for free at:

https://www.erionline.net/BMRN.pdf

On Tuesday, shares in Sangamo Biosciences Inc. ended the session 1.27% lower at $6.97. The stock reported a trading volume of 1.11 million shares, below its three months average volume of 1.19 million shares. Sangamo Biosciences Inc.'s shares have plummeted 9.72% in the last one month, 38.54% in the previous three months and 54.17% on YTD basis. The company is trading 15.80% below its 50-day moving average and 44.45% below its 200-day moving average. Moreover, shares of Sangamo Biosciences Inc. have an RSI of 41.20. Free in-depth research on SGMO is available at:

https://www.erionline.net/SGMO.pdf

--

About Equity Research Institute: 

Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ERI has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA(R) charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ERI, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit www.erionline.net [http://www.erionline.net ].

RESTRICTIONS 

ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.

CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE www.erionline.net

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANGAMO THERAPEUTICS INC
11/21 SANGAMO THERAPEUTICS : Announces Treatment of First Patient in Landmark Phase 1/..
11/17 SANGAMO THERAPEUTICS INC : Featured Company News - Sangamo Announced Treatment o..
11/16 SANGAMO THERAPEUTICS : Announces Plans For New Headquarters In Brisbane, Califor..
11/15 SANGAMO THERAPEUTICS : Hikes on Genome Editing
11/15 SANGAMO THERAPEUTICS : Announces Treatment of First Patient in Landmark Phase 1/..
11/14 SANGAMO THERAPEUTICS, INC : Change in Directors or Principal Officers, Financial..
11/09 SANGAMO THERAPEUTICS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
11/09 SANGAMO THERAPEUTICS : reports 3Q loss
11/09 SANGAMO THERAPEUTICS, INC : Results of Operations and Financial Condition, Finan..
11/09 SANGAMO THERAPEUTICS : Reports Third Quarter 2017 Financial Results
More news
News from SeekingAlpha
11/16 Sangamo's Powerful Pipeline Drives Significant Upside
11/16 Sangamo Therapeutics (SGMO) Presents At Jefferies 2017 London Healthcare Conf..
11/16 FDA OKs Roche's Hemlibra for hemophilia A
11/15 Sangamo's big move continues after Piper upgrade
11/15 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am